Journal Article
. 2013 Mar;26(5).
doi: 10.1038/modpathol.2013.36.

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

Molly E Klein 1 David J Dabbs  Yongli Shuai  Adam M Brufsky  Rachel Jankowitz  Shannon L Puhalla  Rohit Bhargava  
Affiliations
  • PMID: 23503643
  •     29 References
  •     47 citations

Abstract

Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers. The result is reported as a recurrence score ranging from 0 to 100, divided into low-risk (<18), intermediate-risk (18-30), and high-risk (≥31) categories. Our pilot study showed that recurrence score can be predicted by an equation incorporating standard morphoimmunohistologic variables (referred to as original Magee equation). Using a data set of 817 cases, we formulated three additional equations (referred to as new Magee equations 1, 2, and 3) to predict the recurrence score category for an independent set of 255 cases. The concordance between the risk category of Oncotype DX and our equations was 54.3%, 55.8%, 59.4%, and 54.4% for original Magee equation, new Magee equations 1, 2, and 3, respectively. When the intermediate category was eliminated, the concordance increased to 96.9%, 100%, 98.6%, and 98.7% for original Magee equation, new Magee equations 1, 2, and 3, respectively. Even when the estimated recurrence score fell in the intermediate category with any of the equations, the actual recurrence score was either intermediate or low in more than 80% of the cases. Any of the four equations can be used to estimate the recurrence score depending on available data. If the estimated recurrence score is clearly high or low, the oncologists should not expect a dramatically different result from Oncotype DX, and the Oncotype DX test may not be needed. Conversely, an Oncotype DX result that is dramatically different from what is expected based on standard morphoimmunohistologic variables should be thoroughly investigated.

The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.
Isil Z Yildiz-Aktas, David J Dabbs, Rohit Bhargava.
Mod Pathol, 2012 Mar 31; 25(8). PMID: 22460807
A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.
Geza Acs, Nicole N Esposito, +2 authors, Christine Laronga.
Mod Pathol, 2011 Dec 17; 25(4). PMID: 22173289
Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.
K S McCarty, L S Miller, +2 authors, K S McCarty.
Arch Pathol Lab Med, 1985 Aug 01; 109(8). PMID: 3893381
Highly Cited.
Changes in mitotic rate and cell cycle fractions caused by delayed fixation.
K Donhuijsen, U Schmidt, +2 authors, V Budach.
Hum Pathol, 1990 Jul 01; 21(7). PMID: 2193874
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
C W Elston, I O Ellis.
Histopathology, 1991 Nov 01; 19(5). PMID: 1757079
Highly Cited.
The Nottingham Prognostic Index in primary breast cancer.
M H Galea, R W Blamey, C E Elston, I O Ellis.
Breast Cancer Res Treat, 1992 Jan 01; 22(3). PMID: 1391987
Highly Cited.
Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.
S E Pinder, P Wencyk, +6 authors, I O Ellis.
Br J Cancer, 1995 Jan 01; 71(1). PMID: 7819031    Free PMC article.
Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma.
H Pereira, S E Pinder, +5 authors, I O Ellis.
Histopathology, 1995 Sep 01; 27(3). PMID: 8522285
Prognostic factors in primary breast carcinoma.
S E Pinder, I O Ellis, C W Elston.
J Clin Pathol, 1995 Nov 01; 48(11). PMID: 8543641    Free PMC article.
A computer program to assist in making breast cancer adjuvant therapy decisions.
P M Ravdin.
Semin Oncol, 1996 Feb 01; 23(1 Suppl 2). PMID: 8614844
A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients.
P M Ravdin.
Bull Cancer, 1995 Dec 01; 82 Suppl 5. PMID: 8680066
The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables.
E Bergers, I Jannink, +4 authors, J P Baak.
Hum Pathol, 1997 Jan 01; 28(1). PMID: 9013839
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +22 authors, College of American Pathologists.
J Clin Oncol, 2006 Dec 13; 25(1). PMID: 17159189
Highly Cited.
Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.
Maureen Cronin, Chithra Sangli, +7 authors, Drew Watson.
Clin Chem, 2007 Apr 28; 53(6). PMID: 17463177
Highly Cited.
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
A Goldhirsch, W C Wood, +4 authors, 10th St. Gallen conference.
Ann Oncol, 2007 Aug 07; 18(7). PMID: 17675394
Highly Cited. Review.
Histopathologic variables predict Oncotype DX recurrence score.
Melina B Flanagan, David J Dabbs, +2 authors, Rohit Bhargava.
Mod Pathol, 2008 Mar 25; 21(10). PMID: 18360352
Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score.
Katja Gwin, Marguerite Pinto, Fattaneh A Tavassoli.
Int J Surg Pathol, 2009 Jul 07; 17(4). PMID: 19578051
Impact of biospecimens handling on biomarker research in breast cancer.
Loris De Cecco, Valeria Musella, +6 authors, Maria Grazia Daidone.
BMC Cancer, 2009 Nov 26; 9. PMID: 19930681    Free PMC article.
A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
Ping Tang, Jianmin Wang, +9 authors, Gary Lyman.
Cancer Invest, 2010 Aug 10; 28(9). PMID: 20690804
The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.
Joseph Geradts, Sarah M Bean, Rex C Bentley, William T Barry.
Cancer Invest, 2010 Sep 30; 28(9). PMID: 20873988
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
S Sahebjam, R Aloyz, +6 authors, L C Panasci.
Br J Cancer, 2011 Oct 06; 105(9). PMID: 21970880    Free PMC article.
High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.
David J Dabbs, Molly E Klein, +3 authors, Rohit Bhargava.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990395
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
Gong Tang, Jack Cuzick, +6 authors, Norman Wolmark.
J Clin Oncol, 2011 Oct 20; 29(33). PMID: 22010013    Free PMC article.
Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
Jenny J Lee, Jeannie Shen.
Am Surg, 2011 Dec 01; 77(10). PMID: 22127090
Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
K H Allison, P L Kandalaft, +2 authors, A M Gown.
Breast Cancer Res Treat, 2011 Mar 04; 131(2). PMID: 21369717
Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases.
Beth Z Clark, David J Dabbs, Kristine L Cooper, Rohit Bhargava.
Appl Immunohistochem Mol Morphol, 2012 Oct 13; 21(4). PMID: 23060300
Multigene prognostic tests in breast cancer: past, present, future.
Balázs Győrffy, Christos Hatzis, +3 authors, Lajos Pusztai.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848861    Free PMC article.
Highly Cited. Review.
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Bradley M Turner, Kristin A Skinner, +6 authors, David G Hicks.
Mod Pathol, 2015 May 02; 28(7). PMID: 25932962
A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.
Michele M Gage, Martin Rosman, +6 authors, Lorraine Tafra.
Clin Breast Cancer, 2015 Jun 15; 15(6). PMID: 26072275    Free PMC article.
Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer.
Lik Hang Lee, Paul E Swanson, +2 authors, Hua Yang.
Appl Immunohistochem Mol Morphol, 2015 Sep 16; 25(1). PMID: 26371428    Free PMC article.
Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score.
Thaer Khoury, Xiao Huang, +3 authors, Mateusz Opyrchal.
Appl Immunohistochem Mol Morphol, 2016 Jan 26; 24(10). PMID: 26808126    Free PMC article.
Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey.
Vahit Ozmen, Ajlan Atasoy, +7 authors, Pinar Saip.
Cureus, 2016 Apr 16; 8(3). PMID: 27081583    Free PMC article.
Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Su Hyun Lee, Seunggyun Ha, +9 authors, Gi Jeong Cheon.
Eur J Nucl Med Mol Imaging, 2016 May 23; 43(9). PMID: 27209424
Breast cancer: The 21-gene recurrence score - biology remains at the forefront.
Shannon L Puhalla, Nancy E Davidson.
Nat Rev Clin Oncol, 2016 Jun 15; 13(8). PMID: 27296295
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Adam M Brufsky, Nancy E Davidson.
Clin Cancer Res, 2016 Aug 16; 22(20). PMID: 27521446    Free PMC article.
Automated Tubule Nuclei Quantification and Correlation with Oncotype DX risk categories in ER+ Breast Cancer Whole Slide Images.
David Romo-Bucheli, Andrew Janowczyk, +2 authors, Anant Madabhushi.
Sci Rep, 2016 Sep 08; 6. PMID: 27599752    Free PMC article.
Estimating the OncotypeDX score: validation of an inexpensive estimation tool.
Anne A Eaton, Catherine E Pesce, +5 authors, Mahmoud El-Tamer.
Breast Cancer Res Treat, 2016 Dec 09; 161(3). PMID: 27928699    Free PMC article.
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Hyun-Seok Kim, Christopher B Umbricht, +22 authors, Leslie Cope.
J Clin Oncol, 2016 Dec 22; 34(36). PMID: 27998227    Free PMC article.
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Michael R Harowicz, Timothy J Robinson, +4 authors, Maciej A Mazurowski.
Breast Cancer Res Treat, 2017 Jan 09; 162(1). PMID: 28064383    Free PMC article.
Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer.
Theresa A Koleck, Catherine M Bender, +7 authors, Yvette P Conley.
Cancer Med, 2017 Jan 14; 6(2). PMID: 28083945    Free PMC article.
MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.
Einas M Yousef, Daniela Furrer, +4 authors, Louis A Gaboury.
Mod Pathol, 2017 Jan 14; 30(5). PMID: 28084344
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Amila Orucevic, John L Bell, Alison P McNabb, Robert E Heidel.
Breast Cancer Res Treat, 2017 Mar 01; 163(1). PMID: 28243897    Free PMC article.
Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey.
Vahit Özmen, Ajlan Atasoy, +9 authors, Pınar Saip.
J Breast Health, 2016 Jan 01; 12(3). PMID: 28331745    Free PMC article.
21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.
Julie A Lynch, Brygida Berse, Nicole Coomer, John Kautter.
Genet Med, 2017 Mar 24; 19(10). PMID: 28333918
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
Daniel J Farrugia, Alessandra Landmann, +13 authors, Rohit Bhargava.
Mod Pathol, 2017 May 27; 30(8). PMID: 28548119
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Gulisa Turashvili, Edi Brogi, +4 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jun 04; 165(1). PMID: 28577081    Free PMC article.
Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?
Zhongwei Zhao, Carsten Stephan, +3 authors, Klaus Jung.
Int J Mol Sci, 2017 Sep 22; 18(10). PMID: 28934131    Free PMC article.
Review.
Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.
Chieh-Yu Lin, Kelly Mooney, +5 authors, Kimberly Allison.
Mod Pathol, 2017 Dec 16; 31(4). PMID: 29243740
The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Satbir Singh Thakur, Haocheng Li, +5 authors, Hua Yang.
PLoS One, 2018 Jan 06; 13(1). PMID: 29304138    Free PMC article.
A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models.
Ashirbani Saha, Michael R Harowicz, Weiyao Wang, Maciej A Mazurowski.
J Cancer Res Clin Oncol, 2018 Feb 11; 144(5). PMID: 29427210    Free PMC article.
Luminal A Breast Cancer and Molecular Assays: A Review.
Jennifer J Gao, Sandra M Swain.
Oncologist, 2018 Feb 24; 23(5). PMID: 29472313    Free PMC article.
Review.
Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
M M Gage, W C Mylander, +9 authors, R S Jackson.
Ann Oncol, 2018 May 23; 29(5). PMID: 29788166    Free PMC article.
Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
Jon Whitney, German Corredor, +6 authors, Anant Madabhushi.
BMC Cancer, 2018 Jun 01; 18(1). PMID: 29848291    Free PMC article.
Whole-Genome mRNA Gene Expression Differs Between Patients With and Without Delirium.
Katrina Kalantar, Sara C LaHue, +5 authors, Vanja C Douglas.
J Geriatr Psychiatry Neurol, 2018 Jul 12; 31(4). PMID: 29991314    Free PMC article.
Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center.
Hans-Ullrich Voelker, Lea Frey, Annette Strehl, Michael Weigel.
Int J Breast Cancer, 2018 Aug 17; 2018. PMID: 30112216    Free PMC article.
Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Kelsey H Natsuhara, Katya Losk, +7 authors, Rachel A Freedman.
Oncologist, 2018 Aug 05; 24(5). PMID: 30076279    Free PMC article.
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Kathleen Van Asten, Laurence Slembrouck, +16 authors, Patrick Neven.
Oncologist, 2018 Sep 02; 24(2). PMID: 30171067    Free PMC article.
Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing: A Value Study.
Rohit Bhargava, Beth Z Clark, David J Dabbs.
Am J Clin Pathol, 2018 Nov 06; 151(3). PMID: 30395177    Free PMC article.
Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Mustapha Abubakar, Jonine Figueroa, +8 authors, Paul D Pharoah.
Mod Pathol, 2019 Apr 13; 32(9). PMID: 30976105    Free PMC article.
Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system.
Esther C Yoon, Christopher Schwartz, +3 authors, Farbod Darvishian.
Breast J, 2019 Jun 15; 25(5). PMID: 31197914    Free PMC article.
MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis.
Marianne Samir Makboul Issac, Einas Yousef, Muhammad Ramzan Tahir, Louis A Gaboury.
Neoplasia, 2019 Sep 03; 21(10). PMID: 31476594    Free PMC article.
The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer.
Atilla Soran, Kaori Tane, Efe Sezgin, Rohit Bhargava.
Eur J Breast Health, 2020 Apr 15; 16(2). PMID: 32285033    Free PMC article.
Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26.
Bradley M Turner, Mary Ann Gimenez-Sanders, +6 authors, David G Hicks.
Cancer Med, 2019 Jun 15; 8(9). PMID: 31199586    Free PMC article.
The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Napat Saigosoom, Doonyapat Sa-Nguanraksa, +2 authors, Pornchai O-Charoenrat.
Cancer Manag Res, 2020 Apr 21; 12. PMID: 32308485    Free PMC article.
Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls.
Joseph Liu, Anupama Suresh, +18 authors, Robert Wesolowski.
Eur J Breast Health, 2020 Jul 14; 16(3). PMID: 32656521    Free PMC article.
The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer.
Rohit Bhargava, Beth Z Clark, +2 authors, David J Dabbs.
Mod Pathol, 2020 Mar 24; 33(8). PMID: 32203092    Free PMC article.
BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score.
Mark D Zarella, Rebecca C Heintzelman, Nikolay K Popnikolov, Fernando U Garcia.
BMC Clin Pathol, 2018 Dec 24; 18. PMID: 30574014    Free PMC article.
A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Sae Byul Lee, Junetae Kim, +8 authors, Kyung Hae Jung.
Cancer Res Treat, 2018 Nov 06; 51(3). PMID: 30384581    Free PMC article.
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
Mark Laible, Kerstin Hartmann, +7 authors, Annette Ramaswamy.
BMC Cancer, 2019 Jul 17; 19(1). PMID: 31307414    Free PMC article.
Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer.
Abdulmohsen Alkushi, Ahmad Omair, +2 authors, Omalkhair Abualkhair.
Breast Cancer (Auckl), 2020 Dec 22; 14. PMID: 33343196    Free PMC article.
Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.
Rohit Bhargava, Nicole N Esposito, +11 authors, David J Dabbs.
Mod Pathol, 2020 Jul 15; 34(1). PMID: 32661297
Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer.
Laurence Slembrouck, Isabelle Vanden Bempt, +12 authors, Giuseppe Floris.
Mod Pathol, 2021 Feb 10;. PMID: 33558657
Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer.
Minji Koh, Jinhong Jung, +6 authors, Jae Ho Jeong.
Breast Cancer Res Treat, 2021 Apr 24;. PMID: 33891300